Methods for using mosaicism in nucleic acids sampled distal to their origin
Inventors
Assignees
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Abstract
Disclosed herein are methods for improving detection and monitoring of human diseases. The methods can be used to provide spatial and/or developmental localization of the source of each differential mutation within the body. The methods can also be used to generate a mutation map of a subject. And the mutation map can be used to monitoring state(s) of health of one or more tissues of a subject.
Core Innovation
The disclosed subject-matter relates to nucleic-acid-based methods that use genetic mosaicism to create subject-specific mutation maps. Mosaic variants are linked to tissue sources so that differential mutations are spatially and developmental localized, enabling localization of distal nucleic-acid signals using subject-specific mutation maps derived from multi-tissue information.
Mutation maps are generated and used to identify differential mutations by detecting mosaic variants that are present in one nucleic-acid source and absent in another. In particular, the disclosure includes comparing nucleic-acid sequence reads from tissue samples to sequence reads from leukocytes from a blood sample, and the resulting mosaic variants support blood-based tracking of disease-related biology across time using mutation maps.
The disclosure further describes monitoring health states and identifying tumor origin or causal context using mutation maps. Blood samples can be obtained at later time points, and nucleic acid molecules from blood are processed to detect the presence or absence of individual mosaic variants, with the resulting report used for detecting the presence or recurrence of a solid tumor and for providing tumor context tied to the mutation map.
The document also supports technical concepts for low signal and accuracy, including redundant sequencing for low allele fractions and complementary use of cell-free DNA versus cell-surface-bound DNA for time-resolved and higher-sensitivity detection. It additionally addresses optional handling of blood-specific mosaic signals and uses fragmentation patterns associated with apoptosis versus necrosis to support interpretation, and contemplates different sequencing modalities and normalization/reporting outputs, including developmental and spatial trees/body spatial maps.
Claims Coverage
The provided independent claim is clm-00001. It defines an end-to-end tumor detection and recurrence monitoring method that includes identifying mosaic variants by comparing whole genome sequence reads from tissue and matched normal leukocytes, then enriching and tracking those mosaic variants in later blood samples using probe-based enrichment and repeated sequencing to generate a report; the claim thus centers on 7 main inventive steps spanning mapping, longitudinal tracking, and reported detection.
Longitudinal solid tumor detection using mosaic variants
The method detects a presence or recurrence of a solid tumor by identifying mosaic variants from whole genome sequencing comparisons of tissue and matched normal leukocytes, then repeatedly assaying later blood samples for the presence or absence of individual mosaic variants and providing a report based on those observations.
Mosaic variant identification by independent whole genome sequencing of tissue and normal leukocytes
The method generating a first set of sequence reads and a second set of sequence reads by independently performing whole genome sequencing on nucleic acid molecules from a tissue sample (benign, malignant, or mixed) and nucleic acid molecules extracted from leukocytes from a normal first blood sample, then comparing the reads to identify mosaic variants present in the tissue reads and not present in the leukocyte reads.
Time-series sampling and use of non-amplified blood nucleic acids
The method obtains one or more blood samples at a later time point than the first tissue sample and first blood sample, and extracts non-amplified nucleic acid molecules from the one or more later blood samples for downstream enrichment and sequencing.
Probe-based enrichment of blood nucleic acids using biotin-labeled capture probes configured to mosaic variants
The method enriches nucleic acid molecules from the later blood samples using a plurality of biotin-labeled capture probes in solution, where individual instances of the plurality of capture probes are configured to hybridize to individual instances of the mosaic variants identified from the tissue-versus-leukocyte comparison.
Repeated sequencing assay of enriched blood nucleic acids to determine presence or absence of mosaic variants over the life of the subject
The method performs a sequencing assay on the enriched nucleic acid molecules to identify the presence or absence of individual instances of the mosaic variants identified from the initial comparison one or more times over the life of the subject.
Overall, clm-00001 requires mapping mosaic variants by comparing independently generated whole genome sequence reads from tissue and matched normal leukocytes, and longitudinal blood-based tracking by enriching non-amplified later blood nucleic acids with biotin-labeled capture probes configured to hybridize to the identified mosaic variants, followed by repeated sequencing and report generation for detecting presence or recurrence of a solid tumor.
Stated Advantages
Enables detecting the presence or recurrence of a solid tumor in a subject based on a report derived from presence or absence of individual mosaic variants in one or more blood samples.
Documented Applications
Detecting the presence or recurrence of a solid tumor in a subject using tissue-versus-leukocyte mosaic variant identification followed by longitudinal blood sample monitoring.
Interested in licensing this patent?